✦ LIBER ✦

Clinical development plan: Sulindac

✍ Scribed by NCI, DCPC Chemoprevention Branch and Agent Development Committee

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 1010 KB
Volume: 56
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.240560919

No coin nor oath required. For personal study only.

✦ Synopsis

was discovered in a search for a less toxic version of indomethacin, a structurally related compound. Sulindac is indicated for acute and long-term treatment of the symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, shoulder bursitis/ tendinitis, and acute gouty arthritis at doses of 200 to 400 mg qd (ca. 0.008-0.016 mmol/kg-bw qd) [2]. In case studies, sulindac seemed effective in pre-Sulindac is an FDA-approved non-steroidal antiinflammatory (NSAID), antipyretic, and analgesic. As with the other NSAIDs currently being considered by the CB for further development (aspirin, ibuprofen, and piroxicam), sulindac derives its activity from inhibition of cyclooxygenase 11,21. It

📜 SIMILAR VOLUMES

Clinical development plan: Sulindac sulf

Clinical development plan: Sulindac sulfone

📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 772 KB

The NCI, Chemoprevention Branch is developing sulindac sulfone as a chemopreventive agent under a Clinical Trial Agreement with Cell Pathways, Inc. (CPI; Denver, CO). Sulindac sulfone is a metabolite of the FDA-approved nonsteroidal antiinflammatory drug (NSAID) sulindac, also currently under develo

Clinical development plan: Aspirin

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 915 KB

Clinical development plan: Ibuprofen

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

## IBUPROFEN DRUG IDENTIFICATION CAS Registry No.: 15687-27-1 CAS Name (9CI): a-Methyl-4-(2-methylpropyl)benzeneacetic Acid Synonyms: Advil@ (Active Ingredient) Brufen 2-(4-Isobutylphenyl)propionic Acid Midol 1200@ (Active Ingredient) Motrin@ (Active Ingredient) Nuprin@ (Active Ingredient

Clinical development plan: Oltipraz

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 1000 KB

Clinical development plan: Piroxicam

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 926 KB

Clinical development plan: (+)-Vorozole

📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 748 KB